New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:35 EDTNLNKNewLink Genetics price target raised to $35 from $23 at Canaccord
Canaccord is more optimistic that the P3 IMPRESS trial of HyperAcute Pancreas in resected pancreatic cancer could meet its primary endpoint of an improvement in overall survival vs. placebo following a management meeting. Shares are Buy rated.
News For NLNK From The Last 14 Days
Check below for free stories on NLNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NLNK

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use